Highly Potent and Selective N-Aryl Oxamic Acid-Based Inhibitors for Mycobacterium tuberculosis Protein Tyrosine Phosphatase B.

Highly Potent and Selective N-Aryl Oxamic Acid-Based Inhibitors for Mycobacterium tuberculosis Protein Tyrosine Phosphatase B.
复制标题

DOI:
10.1021/acs.jmedchem.0c00302
复制
发表时间:
2020-09-10
影响因子:
7.3
通讯作者:
Zhang ZY
Zhang ZY
中科院分区:
医学1区
文献类型:
--
作者:
Ruddraraju KV;Aggarwal D;Niu C;Baker EA;Zhang RY;Wu L;Zhang ZY

文献摘要

参考文献

被引文献

相似文献

结核病是一种由结核分枝杆菌(Mtb)引起的传染病。结核分枝杆菌蛋白酪氨酸磷酸酶B (mPTPB)是结核分枝杆菌在宿主巨噬细胞中存活所需的毒力因子。因此,mPTPB代表了一个令人兴奋的结核病治疗靶点。在这里,我们发现n -苯基肟酸是一种高效的选择性单酸基磷酸酪氨酸模拟物,可抑制mPTPB。对初始靶点化合物4 (IC50 = 257 nM)的SAR研究发现,mPTPB的几种IC50值低于20 nM的高效抑制剂。其中,化合物4t对mPTPB的Ki值为2.7 nM,优于25种哺乳动物PTPs的4500倍以上。动力学、分子对接和定点诱变分析证实了这些化合物是mPTPB的活性定点可逆抑制剂。这些抑制剂可以逆转细菌磷酸酶诱导的宿主细胞免疫反应的改变。此外,抑制剂的分子量<400 Da,对数D7.4 < 2.5,拓扑极性表面积< 75,配体效率>.43,良好的水溶性和代谢稳定性,从而为进一步的治疗开发提供了良好的起点。
Tuberculosis is an infectious disease caused by the bacterium Mycobacterium tuberculosis (Mtb). Mtb protein tyrosine phosphatase B (mPTPB) is a virulence factor required for Mtb survival in host macrophages. Consequently, mPTPB represents an exciting target for tuberculosis treatment. Here, we identified N-phenyl oxamic acid as a highly potent and selective monoacid-based phosphotyrosine mimetic for mPTPB inhibition. SAR studies on the initial hit, compound 4 (IC50 = 257 nM), resulted in several highly potent inhibitors with IC50 values lower than 20 nM for mPTPB. Among them, compound 4t showed a Ki of 2.7 nM for mPTPB with over 4500-fold preference over 25 mammalian PTPs. Kinetic, molecular docking, and site-directed mutagenesis analyses confirmed these compounds as active site-directed reversible inhibitors of mPTPB. These inhibitors can reverse the altered host cell immune responses induced by the bacterial phosphatase. Furthermore, the inhibitors possess molecular weights <400 Da, log D7.4 < 2.5, topological polar surface area < 75, ligand efficiency > 0.43, and good aqueous solubility and metabolic stability, thus offering excellent starting points for further therapeutic development.
DOI: 10.1016/j.str.2005.07.017
发表时间: 2005-11-01
期刊: STRUCTURE
影响因子: 5.7
作者:
Grundner, C;Ng, HL;Alber, T
通讯作者: Alber, T
DOI: 10.1021/acs.jmedchem.5b01105
发表时间: 2015-09-10
影响因子: 7.3
作者:
Irwin JJ;Duan D;Torosyan H;Doak AK;Ziebart KT;Sterling T;Tumanian G;Shoichet BK
通讯作者: Shoichet BK
DOI: 10.1021/acsmedchemlett.5b00118
发表时间: 2015-07-01
影响因子: 4.2
作者:
He, Rongjun;Yu, Zhi-Hong;Zhang, Zhong-Yin
通讯作者: Zhang, Zhong-Yin
DOI: 10.1021/jm030644s
发表时间: 2004-03-25
影响因子: 7.3
作者:
Halgren, TA;Murphy, RB;Banks, JL
通讯作者: Banks, JL
DOI: 10.1021/jm051256o
发表时间: 2006-10-19
影响因子: 7.3
作者:
Friesner, Richard A.;Murphy, Robert B.;Mainz, Daniel T.
通讯作者: Mainz, Daniel T.